Does PALBOCICLIB Cause Second primary malignancy? 658 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 658 reports of Second primary malignancy have been filed in association with PALBOCICLIB (Ibrance). This represents 0.7% of all adverse event reports for PALBOCICLIB.
658
Reports of Second primary malignancy with PALBOCICLIB
0.7%
of all PALBOCICLIB reports
48
Deaths
109
Hospitalizations
How Dangerous Is Second primary malignancy From PALBOCICLIB?
Of the 658 reports, 48 (7.3%) resulted in death, 109 (16.6%) required hospitalization, and 10 (1.5%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 658 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
METHOTREXATE (414)
Which PALBOCICLIB Alternatives Have Lower Second primary malignancy Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID